相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Vincenza Conteduca et al.
MOLECULAR CANCER THERAPEUTICS (2020)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
Florence Coussy et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
Junko Murai et al.
CELL REPORTS (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2020)
SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway
Chenhao Zhou et al.
THERANOSTICS (2020)
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A. Young et al.
CANCER RESEARCH (2019)
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Junko Murai et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines
Junya Iwasaki et al.
ANTICANCER RESEARCH (2019)
Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
Kevin Shee et al.
PLOS ONE (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Caitlin D. Lowery et al.
CLINICAL CANCER RESEARCH (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
Benedetta Pellegrino et al.
ESMO OPEN (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2,2-difluorodeoxyuridine and their nucleotides
Ellen J. B. Derissen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
Targeting the replication stress response in cancer
Josep V. Forment et al.
PHARMACOLOGY & THERAPEUTICS (2018)
PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)
Alienor Berges et al.
CANCER RESEARCH (2018)
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N. Jones et al.
BRITISH JOURNAL OF CANCER (2018)
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
Kevin M. Foote et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
Alberto Ballestrero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Yanhua Mu et al.
EMBO REPORTS (2016)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
Yanhong Deng et al.
BMC CANCER (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Gabriele Zoppoli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with 19F NMR spectroscopy
Tashinga E. Bapiro et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis
Andrea Ivascu et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
RHJ Mathijssen et al.
BRITISH JOURNAL OF CANCER (2002)
分享论文
